NGD 941

Drug Profile

NGD 941

Latest Information Update: 01 Dec 1997

Price : $50

At a glance

  • Originator Neurogen Corporation
  • Developer Neurogen Corporation; Schering-Plough
  • Class Antipsychotics; Imidazoles; Pyrimidines; Small molecules
  • Mechanism of Action Dopamine D4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Psychotic disorders

Most Recent Events

  • 01 Dec 1997 Discontinued-I for Psychotic disorders in USA (Unknown route)
  • 22 May 1997 Phase-I clinical trials for Psychotic disorders in USA (Unknown route)
  • 07 Feb 1997 No-Development-Reported for Psychotic disorders in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top